

The Manager
Company Announcements Office
ASX Limited

INFORMATION REQUIRED UNDER ASX LISTING RULE 3.10.5A

Adelaide, 12 March 2018: LBT Innovations (“LBT” or the “Company”) (ASX: LBT) provides the following information required under ASX Listing Rule 3.10.5A.

- a. Dilution to existing holders:
The dilutive effect of the 7.1A placement (7,737,999) on existing shareholders is 4.5%.

Further details of the approximate percentage of the issued capital post the placement held by pre-placement shareholders and new shareholders are as follows.

Shareholder category	Holding pre placement	Holding post placement
Pre-placement security holders who did not participate in the placement	100%	95.5%
Pre-placement security holders who did participate in the placement	-	-
Participants in the placement who were not previously security holders	-	4.5%
Total	100%	100%

- b. As advised to the ASX on 6 March 2018, the Company has resolved to utilise the capacity available to it under ASX Listing Rule 7.1A. The Company considers this to be the most effective and expedient method for raising funds to meet working capital requirements. Existing shareholders are also being offered the opportunity to acquire ordinary shares at the same placement price under a Share Purchase Plan. The Share Purchase Plan offer document will be despatched to shareholders on 14 March 2018.
- c. No underwriting arrangements were in place for the placement, and
- d. Fees incurred in connection with the 7.1A placement were 6% of the funds raised or \$69,642.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) uses artificial intelligence (AI) to improve patient outcomes, making healthcare more efficient. The company has developed a patent protected machine learning and intelligent imaging platform technology to deliver the only FDA cleared instrument utilising AI technology in clinical microbiology. Based in Adelaide, South Australia, the Company has two world class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and the Automated Plate Assessment System (APAS®). LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH to commercialise APAS® products. LBT has extended its core FDA Cleared AI technology in the area of chronic wound management. WoundVue® is prototype hand-held device which automatically analyses and records progress of long-term chronic wounds.



CONTACTS

LBT Innovations	Media Relations
<p>Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com</p>	<p>Sarah Kemter Monsoon Communications Tel: +61 3 9620 3333 E: sarahk@monsoon.com.au</p>